How Long Before Preventive Migraine Treatment Shows Results? What Follow-Up Visits Assess

The prescription has been in the bathroom cabinet for three weeks. The migraines have not stopped. You had one on Tuesday, another that crept in over Friday’s dinner, and now you are standing in the kitchen wondering whether this medicine is doing anything at all, or whether you should just quietly give up on it.

That doubt is one of the most common reasons preventive treatment fails, and it has little to do with the medicine. It has to do with expectations. Ask a neurologist how long preventive migraine treatment takes to show results and you will not get a single number; you will get a range, a set of conditions, and a request for a diary.

This explainer walks through that range honestly: what is happening during the quiet early weeks, what your clinician is actually looking for when you come back, and how the decision to continue, adjust or stop is made.

How long preventive migraine treatment takes: the honest range

Here is the number most people want and most clinicians hesitate to give: for the older oral preventives, the usual review point is somewhere between eight and twelve weeks after reaching a steady dose. Mayo Clinic notes that preventive medicines may take several weeks to have an effect, and Cleveland Clinic describes a trial of a few months before deciding whether a medicine is helping. That is the guideline-level answer, and it is deliberately unhurried.

Why so long? Partly because migraine is a fluctuating condition. A person who averages six attacks a month might have three in one month and nine in the next without anything changing. A two-week trial cannot tell signal from noise; a two- or three-month trial can. The other reason is that many oral preventives are introduced gradually, so the clock for judging benefit does not start on the day of the first tablet but weeks later, once the intended dose is reached.

Newer treatments aimed at a molecule called calcitonin gene-related peptide, or CGRP (a chemical messenger released around blood vessels during migraine), are often reviewed on a somewhat shorter timeline, because in trials some people noticed change within the first month. Even so, guidelines generally recommend judging them over a period of at least three months before declaring them ineffective.

So the honest range is: weeks to notice a possible shift, two to three months to know. That is the framework every follow-up visit is built around, and it is why the single most useful thing you can bring to that visit is not a story but a record.

What is the difference between prevention and treatment in migraine?

People searching for this question are often asking something practical: why am I taking a pill every day if I already have something for the pain? The answer lies in two very different jobs.

Acute, or abortive, treatment is taken when an attack begins. Its goal is to shorten or stop that single episode. Over-the-counter pain relievers, triptans (a class of medicines that narrow swollen blood vessels and calm pain signalling) and the newer CGRP receptor antagonists used at attack onset all fall into this group. You judge acute treatment within hours: did the attack ease, and how quickly?

Preventive, or prophylactic, treatment is taken on a schedule whether or not you have a headache that day. Its goal is to make attacks less frequent, less severe and shorter over time, and to make acute medicines work better when you do need them. You judge preventive treatment over months, not hours.

This distinction matters for follow-up because the two are assessed with different yardsticks. A person might report that their acute medicine “works fine” while their preventive “does nothing”, when in fact the diary shows attacks have dropped from eight days a month to five. The preventive is doing its job; it simply does not feel dramatic in the moment.

A related search, “is a new patient visit considered preventive care?”, comes from insurance terminology rather than neurology. In that context, preventive care means routine check-ups and screening in healthy people. A migraine consultation is diagnostic and therapeutic care for an existing condition, even when the therapy itself is called preventive. The word overlaps; the meaning does not.

How preventive migraine treatment actually works in the brain

Migraine is now understood as a disorder of brain excitability rather than a simple blood-vessel problem. The National Institute of Neurological Disorders and Stroke describes it as a neurological condition in which nerve pathways, brain chemicals and blood vessels interact abnormally, producing pain, sensitivity to light and sound, and nausea. Preventives work by nudging that excitable system toward a calmer baseline.

Different classes do this in different ways, which is why they are not interchangeable and why response times differ:

• Beta blockers, originally developed for blood pressure, appear to dampen the stress-related signalling that can trigger attacks.
• Tricyclic antidepressants, used in migraine at levels unrelated to mood treatment, alter serotonin and noradrenaline signalling that modulates pain.
• Anti-seizure medicines reduce the tendency of nerve cells to fire in excitable bursts.
• CGRP-targeting medicines, whether monoclonal antibodies (laboratory-made proteins designed to bind one specific target) or small-molecule antagonists, block the peptide itself or its receptor.
• OnabotulinumtoxinA, used for chronic migraine, is thought to reduce the release of pain-signalling chemicals from nerve endings around the head and neck.

None of these changes happen overnight. Nerve signalling adapts gradually, receptor sensitivity shifts over weeks, and the threshold at which a trigger becomes an attack rises slowly. Think of it less like a light switch and more like adjusting a thermostat in a large, drafty house: the room temperature lags behind the setting.

Which class is chosen depends on your other health conditions, other medicines, and your own priorities, and that choice sits entirely with your prescribing clinician. What the mechanism tells you as a patient is simply this: the early quiet weeks are not wasted; they are the treatment working below the surface.

Who is usually offered prevention, and who is usually asked to wait

Preventive treatment is not the default for everyone with migraine. Most people with occasional attacks manage well with acute medicine and trigger awareness, and adding a daily medicine to that picture brings side effects without much to gain.

Guidelines from bodies such as the NHS and major US centers describe a fairly consistent set of situations where prevention is usually discussed:

• Frequent attacks, commonly described as four or more migraine days a month, or fewer attacks that are unusually long or disabling.
• Acute medicines that do not work well, are not tolerated, or cannot be used because of another condition.
• Acute medicine being taken on so many days that it risks medication overuse headache (a pattern in which frequent pain-relief use itself perpetuates headaches, discussed later).
• Uncommon forms of migraine with prolonged or worrying aura features, where the clinician judges the risk of attacks to be higher.
• Chronic migraine, defined by Cleveland Clinic and Mayo Clinic as headache on 15 or more days a month for more than three months, with migraine features on at least eight of those days.

Who is usually asked to wait? Someone whose attacks are infrequent and respond well to acute treatment. Someone who has just started a new lifestyle approach, such as regular sleep or a headache diary, and whose clinician wants a clearer baseline first. Someone who is pregnant or planning pregnancy, because several preventive classes are avoided in that setting and the discussion needs more care. And, importantly, someone whose headache diagnosis is not yet certain; a preventive started before the pattern is understood can confuse the picture.

Waiting is not the same as being dismissed. In many cases it means gathering the eight weeks of diary information that will make the eventual decision, whatever it is, a better one.

Migraine prevention medication timeline, class by class

People often ask why a friend on an injectable felt different within a month while they have been waiting three months on a tablet. The answer is that assessment windows genuinely differ by class. The table below summarizes typical timelines described in mainstream clinical references; they are ranges, not promises, and your own clinician’s plan may differ for good reasons.

Preventive class	How it is thought to work	Typical point at which effect is assessed	What follow-up usually checks
Beta blockers	Dampen stress-related signalling	About 2–3 months at a steady dose	Heart rate, blood pressure, tiredness, exercise tolerance
Tricyclic antidepressants	Modulate pain-related neurotransmitters	About 2–3 months at a steady dose	Sleep quality, dry mouth, drowsiness, weight change
Anti-seizure medicines	Reduce nerve-cell excitability	About 2–3 months at a steady dose	Concentration, tingling, appetite, mood, pregnancy planning
CGRP monoclonal antibodies	Block CGRP or its receptor	Often reviewed after about 3 months of use	Injection-site reactions, constipation, overall migraine days
OnabotulinumtoxinA (chronic migraine only)	Reduces release of pain-signalling chemicals	Usually judged after two treatment cycles	Neck weakness, eyelid drooping, headache-day count

Two patterns stand out. First, the older oral classes share roughly the same window, because all of them are introduced gradually and act on slowly adapting systems. Second, the CGRP antibodies and onabotulinumtoxinA are judged in cycles rather than in weeks, because they are given at intervals and their effect is expected to build across doses.

Mayo Clinic and Cleveland Clinic both stress that a preventive should not be labelled a failure before it has had an adequate trial at an adequate dose. That single principle prevents more abandoned treatments than any other piece of advice in migraine care.

What the first weeks on a preventive usually look like

Week one rarely feels like progress. If anything, the most noticeable change is side effects rather than benefit, because side effects tend to appear before the therapeutic effect does. A beta blocker may bring tiredness or cold hands; a tricyclic may make mornings groggy; an anti-seizure medicine may cause tingling in the fingers or a flattened appetite. Many of these settle over two to four weeks as the body adjusts, which is one reason clinicians ask people to hold steady rather than stop at the first unwelcome sensation.

Weeks two to six are the frustrating middle. Attacks may continue at their usual rate. Some people notice that attacks feel slightly less intense or respond a little better to acute medicine, an early hint that the threshold is rising. Others notice nothing. Both are normal, and neither predicts the final result.

Around weeks eight to twelve, a genuine pattern usually becomes visible in a diary, if there is one. This is the point at which the first substantive follow-up is generally scheduled. It is also, not coincidentally, the point at which many people who have been keeping no record find they cannot say with confidence whether they are better, because memory smooths out the highs and lows.

A few practical things make this stretch easier. Take the medicine at the same time each day so that missed doses do not muddy the assessment. Keep using your acute treatment as prescribed; the preventive is not meant to replace it. Note side effects with dates rather than trying to recall them later. And resist the temptation to add a new supplement or make a dramatic lifestyle change in the same month, because every additional variable makes the follow-up harder to interpret.

How to track migraine frequency so follow-up visits mean something

A headache diary is the single most important tool in judging how long preventive migraine treatment takes for you specifically, and it is astonishing how often it is skipped. Without it, a follow-up visit becomes two people guessing. With it, the visit becomes a comparison of numbers.

What to record does not need to be complicated. Mainstream references, including the NHS and Mayo Clinic, suggest tracking:

• Each day with any headache, and whether it had migraine features such as throbbing pain, nausea, or sensitivity to light and sound.
• How severe the day was, on a simple scale you use consistently.
• Whether you took acute medicine, and what kind, without needing to note amounts.
• Whether the attack stopped you working, studying or caring for others.
• Possible contributing factors: poor sleep, skipped meals, menstrual timing, unusual stress, alcohol.

The two numbers your clinician will care about most are monthly headache days and monthly migraine days. Headache days count any day with head pain; migraine days count those with migraine features. A preventive can lower one without much changing the other, and that distinction affects how the treatment is judged.

Paper works, a wall calendar works, and so do smartphone apps. What matters is that recording happens the same day rather than being reconstructed a week later. Ideally the diary starts before the preventive does, giving a baseline of at least a month, and continues without gaps through the assessment period.

One subtle point: a diary also records what did not happen. A month with two fewer attacks than usual is easy to forget, because absence leaves no memory. The diary is the only witness to those quiet days, and those quiet days are the whole point of the treatment.

What follow-up visits assess: the first check-in

The first follow-up after starting a preventive often comes earlier than the full assessment point, sometimes within four to six weeks, and its purpose is different. This visit is about tolerability and safety, not yet about success.

Your clinician will typically want to know whether you have been able to take the medicine consistently. Missed doses are common and are not a moral failing, but they change the interpretation of everything else. They will ask about side effects in some detail: which ones, when they started, whether they are fading. For certain classes there are specific checks, such as blood pressure and pulse with beta blockers, or mood and concentration with anti-seizure medicines.

The visit is also when adjustment may be discussed. Many oral preventives are stepped up gradually, and this check-in is the natural moment to confirm that the intended level has been reached or to slow the pace if side effects are troublesome. Any such change belongs to the prescriber; the diary simply informs it.

Expect a glance at the diary even at this stage, but do not expect a verdict. A clinician who declares a preventive a success or failure at week five is working from too little information, and most will say so. What they may do is look for early warning signs that the treatment is a poor fit: intolerable side effects, a new medical issue, or a clear interaction with another medicine.

Finally, this visit usually confirms the plan for acute treatment during the trial. The preventive and the acute medicine are meant to work together, and clarifying which days to use what avoids the medication-overuse trap described further down.

What chronic migraine follow-up visits look for over months

For people with chronic migraine, follow-up is less a single visit than a series, because chronic migraine tends to move slowly in both directions. Cleveland Clinic describes it as headache on 15 or more days a month for over three months, and improvement is often measured as a gradual retreat below that threshold rather than a sudden disappearance.

At the two- to three-month review, the diary comparison is the centrepiece. Your clinician will look at the change in monthly migraine days against your baseline, the change in headache days overall, whether attacks that still occur are shorter or milder, and how often acute medicine was needed. Function matters as much as counts: fewer missed workdays, or being able to keep a family commitment, are legitimate markers of benefit even when the numbers move modestly.

Several questions shape the next step. Has the medicine had a fair trial at an adequate level for long enough? If not, continuing is usually the sensible course. If yes, and the benefit is meaningful, the conversation turns to how long to continue. If yes, and the benefit is minimal or side effects outweigh it, the discussion moves to alternatives, which may mean a different class, a combination, or a non-drug approach.

Later visits, often at three- to six-month intervals once someone is stable, monitor for drift. Migraine patterns change with life stages, sleep, stress and hormones, and a preventive that suited a person at one point may need revisiting later. These visits also revisit contributing conditions that commonly travel with chronic migraine, such as disturbed sleep, anxiety, depression and neck pain, because treating those can shift the migraine picture independently.

What "working" means: the 50 percent benchmark and beyond

Clinical trials of migraine preventives usually report the proportion of participants whose monthly migraine days fell by at least half, and this 50 percent figure has become a common shorthand in clinics. Cleveland Clinic describes the goal of preventive treatment in similar terms: reducing how often attacks happen and how severe they are, with a halving of frequency often used as the marker of a good response.

The benchmark is useful, but it should not be mistaken for a pass mark. Someone whose attacks drop from twelve days a month to eight has not reached 50 percent, yet has gained four days a month, nearly fifty a year. For many people that is a meaningful change in a working life. Conversely, someone whose count falls by half but whose remaining attacks are just as long and disabling may feel less improved than the number suggests.

That is why follow-up visits weigh several dimensions together:

• Frequency: how many migraine and headache days per month.
• Severity: how intense the attacks that still happen are.
• Duration: whether attacks resolve faster.
• Acute medicine response: whether pain relief works more reliably.
• Disability: whether the condition interferes less with work, study, sleep and relationships.

It is also worth knowing what a preventive is not expected to do. It is not expected to eliminate all attacks, and a clinician who frames the goal as “no more migraines” is setting up disappointment. The realistic aim, in the language most guidelines use, is to control and manage migraine so that it takes up less of your life. Measured against that aim, partial success is still success, and the decision about whether it is enough belongs to you and your treating team together.

Why medication overuse can hide a working preventive

One of the quieter reasons preventive treatment appears to fail is that something else is keeping the headaches going. Medication overuse headache, sometimes called rebound headache, is a pattern in which frequent use of acute pain relief itself sustains near-daily head pain. The NHS notes that this can develop when painkillers or triptans are taken on many days each month over a prolonged period, and Mayo Clinic gives a similar description.

The mechanism is counterintuitive. Repeated exposure to acute medicines appears to sensitize pain pathways, so that as each dose wears off the head pain returns, prompting another dose. The result is a cycle that a preventive cannot easily break on its own. Someone caught in this cycle may take a preventive faithfully for three months, record no improvement in their diary, and conclude the medicine does not work, when in fact the overuse pattern is masking any benefit.

This is why follow-up visits ask not just about migraine days but about days on which acute medicine was used. A diary that shows pain relief on most days of the month is a signal in itself, regardless of what the preventive is doing. The clinician may suggest addressing the overuse pattern first or alongside, and that process, which can involve a temporary worsening before improvement, needs to be planned and supervised rather than attempted alone.

The practical takeaway is simple: record every day you take acute medicine, including over-the-counter products, and be candid about it. Nobody is being judged. The information changes the interpretation of the whole trial, and it can turn an apparent failure into a solvable problem.

Examples of preventive measures beyond medicine, and how long they take

When people search for “what counts as preventive care” or “examples of preventive measures” in the context of migraine, they are usually asking whether there are things they can do themselves that carry weight. There are, and they have timelines too.

Regular sleep is the most consistently cited. Both too little and too much sleep are recognized triggers, and a stable wake time seven days a week is a preventive measure in its own right. Regular meals and steady hydration address the blood-sugar dips and dehydration that many people identify as triggers. Regular aerobic exercise, built up gradually, is associated with fewer attacks in observational and small trial data, though vigorous exertion can trigger attacks in some people, so pacing matters.

Behavioural approaches have a stronger evidence base than many realize. Cognitive behavioural therapy adapted for headache, relaxation training and biofeedback (a technique in which sensors help a person learn to control muscle tension or skin temperature) are recommended in mainstream references as preventive options, either alone or alongside medicine. Their effect tends to build over eight to twelve weeks of regular practice, a timeline similar to oral preventives.

Supplements such as riboflavin, magnesium and coenzyme Q10 are mentioned in NIH Office of Dietary Supplements and Mayo Clinic material as having some supportive evidence, generally of modest quality. They are not a substitute for prescribed treatment, they can interact with other medicines, and any trial of them should be discussed with your clinician rather than started quietly mid-way through a medication trial.

Notice the common thread: consistency over weeks, not intensity over days. Migraine prevention, whatever the tool, rewards the boring virtue of doing the same thing every day.

When to stop migraine preventive treatment, and how that decision is made

Nobody expects to take a preventive forever, and the question of when to stop usually surfaces once things are going well. Guidelines are cautious here, and the general approach described by the NHS and by major US centers is that after a sustained period of good control, often described as around six to twelve months, a supervised trial of gradually reducing the medicine may be considered to see whether the improvement holds.

The word “supervised” is doing real work in that sentence. Stopping some preventives abruptly, beta blockers in particular, can cause rebound effects on heart rate and blood pressure, and stopping others suddenly can bring a swift return of attacks. Reduction is therefore planned with the prescriber, usually stepped down over weeks, with the diary continuing throughout so that any relapse is caught early.

Several factors shape the decision:

• How long control has been stable, and how complete it has been.
• Whether the original reasons for starting, such as frequency or medication overuse, have resolved.
• Whether side effects have become burdensome.
• Life changes, including pregnancy planning, new medical conditions or new medicines.
• Your own preference about taking a daily medicine.

Some people find that attacks stay infrequent after stopping, suggesting the migraine pattern itself has quietened, perhaps with age or changed circumstances. Others find attacks return within weeks, and restarting is a reasonable option that the clinician can guide. Neither outcome is a failure; both are information.

What the evidence does not support is stopping on your own because you feel better, or because you missed a few doses and nothing happened. The diary that guided starting the medicine should guide stopping it too, and the decision sits with you and your treating team, not with a good fortnight.

What people often get wrong about how long preventive migraine treatment takes

Myth: if it were going to work, I would feel something by now. Two or three weeks is almost never long enough for an oral preventive to show a clear benefit, and early side effects can make people feel worse before they feel better. Mayo Clinic and Cleveland Clinic both frame the assessment period in months.

Myth: a preventive should stop all my migraines. No mainstream guideline sets that as the goal. The aim is fewer, milder, shorter attacks and better response to acute treatment. Judged against an impossible standard, every preventive fails.

Myth: if one medicine in a class did not help, none of them will. Response to preventives is highly individual. Someone who gained nothing from one class may respond well to another with a different mechanism, which is why clinicians often describe a sequence of trials rather than a single attempt.

Myth: I can skip the diary because I will remember. Memory compresses. People consistently overestimate how frequent their headaches were before treatment and underestimate improvement, or the reverse. The diary is not bureaucracy; it is the measuring instrument.

Myth: taking more pain relief while I wait is harmless. Frequent acute medicine use can drive medication overuse headache, which masks any preventive benefit and can make the follow-up visit uninterpretable.

Myth: once it works, I can stop whenever I like. Stopping is a planned, supervised process, partly because some classes should not be stopped abruptly and partly because a slow reduction tells you whether the benefit holds.

Myth: the newest treatment is always the fastest and best. Newer CGRP-targeting medicines are reviewed on a somewhat shorter timeline, but they are not suitable for everyone, and older classes remain first-line options in many guidelines for good reasons of evidence, safety and fit with other conditions.

Questions to ask your care team about your preventive trial

A follow-up visit goes better when you arrive with your diary and a short list. These questions are drawn from what people most often wish they had asked.

• When does the assessment clock start for this particular medicine: from the first day, or from when I reach the intended level?
• Roughly how many weeks or months should I expect before we decide whether it is helping, and what will that decision be based on?
• Which side effects are likely to fade with time, and which ones should prompt me to call before the next appointment?
• How should I record my headaches so the information is most useful to you, and should I start the diary before the medicine?
• On how many days a month is it reasonable to use my acute medicine during this trial, and what should I do if I find myself needing more?
• Are there other medicines, supplements or lifestyle changes I should avoid starting during the trial so we can interpret the result clearly?
• If this preventive does not help enough, what is the likely next step, and how long would that trial take?
• How will we know when it is time to talk about reducing or stopping, and how would that be done safely?
• Does anything about my other health conditions or plans, including pregnancy, affect which preventive suits me?

You do not need answers to all of these at once. The point is to leave each visit knowing three things: what the plan is, what you are measuring, and when you will next review it together. If any of those are unclear, say so before you leave the room. Clinicians would far rather clarify now than discover at the next visit that the trial was misunderstood.

When to call your doctor

Most of preventive migraine treatment is patient, unhurried work, but some situations should not wait for the scheduled follow-up. Contact your clinician promptly if you notice side effects that feel severe or that are getting worse rather than settling, such as marked dizziness, fainting, a very slow heartbeat, new or worsening low mood, thoughts of self-harm, confusion, or an allergic-type reaction with rash, swelling or breathing difficulty. Also call if you find yourself taking acute pain relief on most days of the week, if your headaches change character, or if you are pregnant or planning pregnancy and have not yet discussed your preventive in that light.

Seek emergency care immediately for any headache that is sudden and reaches maximum intensity within seconds or minutes, sometimes described as a thunderclap headache; a headache with fever, stiff neck, rash or confusion; a headache following a head injury; a headache with weakness, numbness, slurred speech, facial drooping or vision loss that does not follow your usual aura pattern; a headache described as the worst of your life; or a new headache pattern after age 50. The NHS and Mayo Clinic list these as features that require urgent assessment, because they may indicate a cause other than migraine.

A headache diary is useful here too. A sudden shift in pattern that stands out against months of records is easier for a clinician to evaluate than a description from memory.

Finally, if you are simply unsure whether something is normal, that is itself a reason to call. Preventive treatment is a partnership over months, and a short conversation between visits is part of how it is meant to work. Every decision about continuing, adjusting or stopping a preventive rests with your treating team, who know your history and can weigh it properly.

Frequently asked questions

How long does it take for migraine preventive medication to start working?

For the older oral classes, a clear effect is usually assessed after about two to three months at a steady dose, according to Mayo Clinic and Cleveland Clinic guidance. Some people notice attacks becoming milder within the first several weeks, while others see no change until later. Newer CGRP-targeting treatments are often reviewed after around three months of use. Your prescriber sets the timeline for your specific medicine.

What is the migraine prevention medication timeline for the newer injectables?

CGRP monoclonal antibodies are given at intervals rather than daily, and their effect is expected to build across doses. Some trial participants noticed change within the first month, but mainstream guidance recommends a trial of at least three months before deciding whether one is helping. Follow-up checks injection-site reactions, constipation and, above all, the change in monthly migraine days recorded in a diary.

What is the difference between prevention and treatment for migraine?

Acute treatment is taken when an attack starts and aims to stop that single episode within hours. Preventive treatment is taken on a regular schedule regardless of symptoms and aims to reduce how often attacks happen, how severe they are and how long they last over months. Most people with frequent migraine use both together, and follow-up visits assess each with different measures.

Is a new patient visit for migraine considered preventive care?

In insurance terminology, no. Preventive care usually means routine check-ups, screening and vaccinations for people without symptoms. A migraine consultation is diagnostic and treatment care for an existing condition, even though the medicine prescribed may be called a preventive. The clinical meaning of the word and the billing meaning overlap in name only, so it is worth checking coverage terms directly.

How do I track migraine frequency before a follow-up visit?

Record every day with any headache, whether it had migraine features, how severe it was on a consistent scale, whether you used acute medicine, and whether it disrupted your day. Note likely contributors such as poor sleep or menstrual timing. Start before the preventive if possible to establish a baseline, and record daily rather than from memory. Monthly headache days and monthly migraine days are the two figures your clinician will focus on.

What do chronic migraine follow-up visits actually check?

They compare your diary with your starting point: monthly migraine and headache days, attack severity and duration, how often acute medicine was needed, and how much migraine interfered with work, sleep and daily life. They also check side effects, adherence, blood pressure or mood where relevant to the medicine, and contributing conditions such as sleep disturbance or anxiety. The outcome shapes whether to continue, adjust or change approach.

When should I consider stopping a migraine preventive?

Guidelines generally describe considering a supervised, gradual reduction after a sustained period of good control, often around six to twelve months. The decision depends on how complete the control has been, side effects, life changes such as pregnancy planning, and your own preference. Some preventives should never be stopped abruptly, so any reduction is planned with your prescriber while the diary continues.

Why does my preventive seem to do nothing even after three months?

Several explanations are possible: the intended dose may not have been reached long enough, missed doses may have diluted the effect, frequent acute pain relief may be causing medication overuse headache that masks benefit, or this class may simply not suit you. Response is highly individual. A follow-up visit with your diary helps your clinician distinguish these and decide the next step.

What counts as preventive care for migraine that is not medicine?

Consistent sleep and wake times, regular meals, steady hydration, gradually built aerobic exercise, and behavioural approaches such as cognitive behavioural therapy, relaxation training and biofeedback are all recognized preventive measures in mainstream references. Their benefit tends to build over eight to twelve weeks of regular practice. Certain supplements have modest supporting evidence but should be discussed with your clinician before use.

Do side effects mean the preventive is not working?

No. Side effects often appear before benefits because they reflect the body adjusting to the medicine, while the therapeutic effect depends on slower changes in nerve signalling. Many settle within two to four weeks. Severe or worsening side effects, or new low mood, should prompt a call to your clinician rather than stopping on your own, since some classes need to be reduced gradually.

References

• Cleveland Clinic: Migraine headaches
• NHS: Migraine
• NIH National Institute of Neurological Disorders and Stroke: Migraine
• MedlinePlus: Migraine

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.